Comparison of blood lead concentrations in patients with acute ischemic stroke and healthy subjects.

Ischemic stroke, lead Toxicity

Journal

Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS)
ISSN: 1878-3252
Titre abrégé: J Trace Elem Med Biol
Pays: Germany
ID NLM: 9508274

Informations de publication

Date de publication:
18 Apr 2020
Historique:
received: 15 12 2019
revised: 02 04 2020
accepted: 06 04 2020
pubmed: 4 5 2020
medline: 4 5 2020
entrez: 4 5 2020
Statut: aheadofprint

Résumé

Stroke is the main cause of mortality and long-term disability in the general population. With the increased application of metals in industries and human environment, lead has become a health hazard. In this study, we aimed to evaluate the relationship between the blood concentration of lead and the incidence of acute stroke. We performed this study during 2016-17 at Vali-e-Asr Hospital in Birjand, Iran, among 80 ischemic stroke patients visiting the hospital and 80 healthy gender- and age-matched controls. Blood lead concentration (BLC) was measured using graphite furnace atomic absorption spectrometry. BLC medians in the case and control groups were 20.65 [5.37-34.87] μg/dL and 2.65 [1.75-13.85] μg/dL, respectively (p < 0.05). The case group had significantly lower mean levels of HDL and phosphors, whereas the mean levels of white blood cells and uric acid were higher in this group. After adjusting for lipid profile and fasting blood sugar, multiple logistic regression indicated that the serum levels of uric acid and BLC were significant for predicting ischemic stroke. It is estimated that the odds ratio of ischemic stroke increases by 1.04 per 1 μg/dl increase in BLC. This study showed that lead can be a risk factor for ischemic stroke. Since it does not have any beneficial effects on the health of individuals, screening serum concentrations of lead can be considered as a preventive strategy for those at risk of stroke.

Sections du résumé

BACKGROUND AND OBJECTIVES OBJECTIVE
Stroke is the main cause of mortality and long-term disability in the general population. With the increased application of metals in industries and human environment, lead has become a health hazard. In this study, we aimed to evaluate the relationship between the blood concentration of lead and the incidence of acute stroke.
MATERIALS AND METHODS METHODS
We performed this study during 2016-17 at Vali-e-Asr Hospital in Birjand, Iran, among 80 ischemic stroke patients visiting the hospital and 80 healthy gender- and age-matched controls. Blood lead concentration (BLC) was measured using graphite furnace atomic absorption spectrometry.
RESULTS RESULTS
BLC medians in the case and control groups were 20.65 [5.37-34.87] μg/dL and 2.65 [1.75-13.85] μg/dL, respectively (p < 0.05). The case group had significantly lower mean levels of HDL and phosphors, whereas the mean levels of white blood cells and uric acid were higher in this group. After adjusting for lipid profile and fasting blood sugar, multiple logistic regression indicated that the serum levels of uric acid and BLC were significant for predicting ischemic stroke. It is estimated that the odds ratio of ischemic stroke increases by 1.04 per 1 μg/dl increase in BLC.
CONCLUSION CONCLUSIONS
This study showed that lead can be a risk factor for ischemic stroke. Since it does not have any beneficial effects on the health of individuals, screening serum concentrations of lead can be considered as a preventive strategy for those at risk of stroke.

Identifiants

pubmed: 32361683
pii: S0946-672X(20)30097-3
doi: 10.1016/j.jtemb.2020.126532
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

126532

Informations de copyright

Copyright © 2020. Published by Elsevier GmbH.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Auteurs

Seyed Mohammad Mousavi-Mirzaei (SM)

Medical Toxicology and Drug Abuse Research Center (MTDRC), Birjand University of Medical Sciences, Birjand, Iran.

Emad Yeganeh Khorasani (EY)

Student research committee, Birjand University of Medical Sciences, Birjand, Iran.

Alireza Amirabadizadeh (A)

Medical Toxicology and Drug Abuse Research Center (MTDRC), Birjand University of Medical Sciences, Birjand, Iran.

Samaneh Nakhaee (S)

Medical Toxicology and Drug Abuse Research Center (MTDRC), Birjand University of Medical Sciences, Birjand, Iran.

Amin Baharshahi (A)

Medical Toxicology and Drug Abuse Research Center (MTDRC), Birjand University of Medical Sciences, Birjand, Iran.

Ali Rajabpour-Sanati (A)

Medical Toxicology and Drug Abuse Research Center (MTDRC), Birjand University of Medical Sciences, Birjand, Iran.

Abolfazl Talebi (A)

Medical Toxicology and Drug Abuse Research Center (MTDRC), Birjand University of Medical Sciences, Birjand, Iran; Student research committee, Birjand University of Medical Sciences, Birjand, Iran.

Roland J Lamarine (RJ)

Professor of Public Health, California State University Chico, California, USA.

Mahsa Mehrpour (M)

Medical Toxicology and Drug Abuse Research Center (MTDRC), Birjand University of Medical Sciences, Birjand, Iran; Department of Persian Medicine, School of Persian and Complementary Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: MehrpourM911@mums.ac.ir.

Omid Mehrpour (O)

Medical Toxicology and Drug Abuse Research Center (MTDRC), Birjand University of Medical Sciences, Birjand, Iran; Rocky Mountain Poison and Drug Safety, Denver, CO, USA.

Classifications MeSH